Cat. No. | Product name | CAS No. |
DC20611 |
A4250
Featured
A4250 (A-4250, Odevixibat) is a small molecule ileal bile acid transporter (IBAT) inhibitor for the treatment of cholestatic liver diseases including progressive familial intrahepatic cholestasis and NASH.. |
501692-44-0 |
DC8406 |
A-438079 HCl
Featured
A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9. |
899431-18-6 |
DC7538 |
A66
Featured
A66 is a potent and specific p110α inhibitor with IC50 of 32 nM, >100 fold selectivity for p110α over other class-I PI3K isoforms. |
1166227-08-2 |
DC5163 |
A-674563
Featured
A-674563 is a potent, orally available Akt1 inhibitor with an IC50 value of 11nM. Also displays activity against PKA and CDK2 with IC50 values of 16nM and 46nM respectively. |
552325-73-2 |
DC7045 |
A-769662
Featured
A-769662 is a potent, reversible AMPK activator with EC50 of 0.8 μM, little effect on GPPase/FBPase activity. |
844499-71-4 |
DC11372 |
A-779
Featured
A-779 is a peptide antagonist of the Mas receptor, also known as the angiotensin (1-7) (Ang (1-7)) receptor (IC50 = 0.3 nM in a radioligand binding assay). |
159432-28-7 |
DC2061 |
A-803467
Featured
A-803467 is a selective NaV1.8 channel blocker with IC50 of 8 nM. |
944261-79-4 |
DC9954 |
A 804598
Featured
A-804598 is a novel, competitive, and selective P2X7 receptor antagonist with IC50 of 10 nM, 9 nM and 11 nM in rat, mouse and human P2X7 receptors respectively. |
1125758-85-1 |
DC7286 |
A83-01
Featured
A83-01 is a selective inhibitor of TGF-β type I receptor ALK5 kinase, type I activin/nodal receptor ALK4 and type I nodal receptor ALK7 (IC50 values are 12, 45 and 7.5 nM respectively). |
909910-43-6 |
DC11304 |
A939572
Featured
A939572 is a potent, and orally bioavailable SCD1 inhibitor with IC50 values of <4 nM and 37 nM for mSCD1 and hSCD1, respectively. |
1032229-33-6 |
DC7046 |
A-966492
Featured
A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively. |
934162-61-5 |
DC20616 |
AA 41612
Featured
AA 41612 is a potent, synthetic melanopsin antagonist with IC50 of 15.8 nM, attenuates melanopsin photocurrent in a dose-dependent manner. |
433690-62-1 |
DC23277 |
AA-115
Featured
AA-115 (APG 115) is a potent and orally active MDM2 inhibitor with Ki <1 nM, potently inhibits SJSA-1 cell growth with IC50 of 60 nM. |
1818393-16-6 |
DC21979 |
ATF6 agonist compound A147
Featured
ATF6 agonist compound A147 is a specific, small molecule agonist of transcription factor ATF6, activates ATF6 and influences differentiation of stem cells.147 has broad antiviral activity against multiple DENV strains and serotypes and that the compound i |
393121-74-9 |
DC10165 |
AA26-9
Featured
AA26-9 is a potent and broad spectrum serine hydrolase inhibitor. |
1312782-34-5 |
DC20618 |
AAI-101
Featured
AAI-101 is a novel extended-spectrum β-lactamase inhibitor with activity against many β-lactamases, including some class A and class D carbapenemases. |
1001404-83-6 |
DC23864 |
AAL993
Featured
AAL993 (ZK260253) is a potent, orally active VEGFR inhibitor with IC50 of 130, 23 and 18 nM for VEGFR-1, 2 and 3, respectively. |
269390-77-4 |
DC10797 |
AB-423
Featured
AB-423 is the first-generation Hepatitis B Virus Capsid Assembly inhibitor, which was generally safe and well tolerated in Phase 1 healthy volunteer studies. |
1572510-80-5 |
DC21981 |
CD73 inhibitor AB-680
Featured
AB680 (AB-680) is a highly potent, selective, reversible inhibitor of CD73 with Ki/IC50 of 4.9/70 pM (hCD73), displays > 10,000-fold selectivity against related ecto-nucleotidases (CD39, NTPDases 2/3/8) and a large panel of unrelated enzymes, receptors, a |
2105904-82-1 |
DC8161 |
Xeglyze(Abametapir)
Featured
Abametapir is the active ingredient of Xeglyze Lotion. |
1762-34-1 |
DC11452 |
ABBV-744
Featured
ABBV-744 is a BDII-selective BET bromodomain inhibitor that is being investigated to treat AML and metastic castration-resistant prostate cancer.BBV-744, a highly potent and selective inhibitor of the BD2 domain of BET family proteins with drug-like properties. In contrast to the broad range of cell growth inhibition induced by DbBi, the antiproliferative activity of ABBV-744 was largely, but not exclusively, restricted to cell lines of acute myeloid leukaemia and prostate cancer that expressed the full-length androgen receptor (AR). ABBV-744 retained robust activity in prostate cancer xenografts, and showed fewer platelet and gastrointestinal toxicities than the DbBi ABBV-07514.Analyses of RNA expression and chromatin immunoprecipitation followed by sequencing revealed that ABBV-744 displaced BRD4 from AR-containing super-enhancers and inhibited AR-dependent transcription, with less impact on global transcription compared with ABBV-075. These results underscore the potential value of selectively targeting the BD2 domain of BET family proteins for cancer therapy. |
2138861-99-9 |
DC11299 |
ABC 1183
Featured
ABC1183 is a potent, selective, orally active GSK3α/β and CDK9 inhibitor with IC50 of 327/657 nM and 321 nM (CDK9/cyclin T1), shows growth inhibitory activity against a broad panel of cancer cell lines; decreases cell survival through G2/M arrest and modu |
1042735-18-1 |